Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $10.96 and last traded at $10.95, with a volume of 179112 shares traded. The stock had previously closed at $11.83.
Analyst Upgrades and Downgrades
BCAX has been the topic of several research reports. HC Wainwright dropped their target price on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research report on Monday. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $36.50.
Read Our Latest Report on BCAX
Bicara Therapeutics Stock Up 11.0 %
The firm has a fifty day moving average of $12.93 and a two-hundred day moving average of $17.19.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.
Hedge Funds Weigh In On Bicara Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company purchased a new position in Bicara Therapeutics in the 3rd quarter valued at $582,000. Wellington Management Group LLP acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $19,458,000. Jane Street Group LLC purchased a new position in Bicara Therapeutics in the 3rd quarter worth approximately $309,000. Barclays PLC acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $255,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $1,239,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
